

Low Dose Interleukin-10 and Anti-IL-1 Antibody in Modulating Intestinal Inflammation

Fioranelli M1* and Roccia MG2

¹University B.I.S. Group of institutions, Punjab Technical University, Punjab, India

²Marconi University, Rome, Italy

*Corresponding author: Fioranelli M, University B.I.S. Group of institutions, Punjab Technical University, Punjab, India, Tel: +61 74 9232008; E-mail: massimo.fioranelli@gmail.com

Rec date: Nov 3, 2014, Acc date: Nov 20, 2014, Pub date: Nov 22, 2014

Copyright: © 2014 Fioranelli M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Clinical Image

This image exemplifies the qualitative evaluation of the structural integrity of the colon which express the Zonula Occludens-1 (ZO-1) tight junctions (TJ) protein. The experiment were performed in order to elucidate the effects of the oral intake of a solution containing interleukin-10 and anti-IL-1 antibody in modulating intestinal

inflammation induced by (Dextran Sodium Sulphate) DSS oral administration in a validated experimental murine model. Immunofluorescence staining anti-ZO-1 (in red) in colon samples of different treatment groups highlight the different epithelial barrier TJ structural integrity (arrows).



Figure 1: This image is reproduced under the terms of the Creative Commons Attribution License.

A significative example for each treatment group is shown: A (UNTR; untreated, hydroalcoholic solution only); B (DSS; DSS 2% plus hydroalcoholic solution); C (DSS+IL-10/anti-IL-1; DSS 2% +interleukin-10 plus anti-IL-1 antibody) Bars: 20 µm. This image

clearly shows that mice treated with low doses of interleukin 10 and anti-IL-1 antibody were comparable to untreated mice, in terms of maintenance of an healthy epithelial structure.